Keros Therapeutics (KROS) Return on Equity (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Return on Equity data on file, last reported at 0.0% in Q4 2025.

• For the quarter ending Q4 2025, Return on Equity rose 1.0% year-over-year to 0.0%; the trailing twelve-month figure through Dec 2025 stood at 0.0% (up 1.0% YoY), and the FY2025 full-year result was 0.0%, up 1.0% from the prior year.
• Return on Equity for Q4 2025 stood at 0.0%, up from 0.0% in the prior quarter.
• Across five years, Return on Equity topped out at 0.0% in Q4 2025 and bottomed at 0.01% in Q4 2023.
• The 5-year median for Return on Equity is 0.0% (2022), against an average of 0.0%.
• The widest annual swing landed in 2021, when Return on Equity slipped 1 bps; it then gained 1 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.0% in 2021, then plunged by 59 bps to 0.0% in 2022, then sank by 34 bps to 0.01% in 2023, then soared by 37 bps to 0.0% in 2024, then surged by 151 bps to 0.0% in 2025.
• The last three Return on Equity figures came in at 0.0% (Q4 2025), 0.0% (Q3 2025), and 0.0% (Q2 2025), per Business Quant data.

Peer Comparison